Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVenture Life Regulatory News (VLG)

Share Price Information for Venture Life (VLG)

Share Price is delayed by 15 minutes
Get Live Data
67.00    0.00 (0.00%)
Bid:
66.00
Ask:
68.00
Spread: 2.00 (3.03%)
Market Cap: £81.62m
VLG Live PriceLast checked at - London Stock Exchange

Intraday Venture Life Share Chart

Directorate Changes

17 May 2022 07:00

RNS Number : 6837L
Venture Life Group PLC
17 May 2022
 

17th May 2022

 

VENTURE LIFE GROUP PLC

("Venture Life" "VLG" or the "Group")

Directorate Changes

 

Venture Life (AIM: VLG), a leader in developing, manufacturing and commercialising products for the self-care market, announces the appointment of Mr Paul McGreevy as Non-executive Chair of the Company with immediate effect and consequent stepping down from the Board of Dr. Lynn Drummond.

Mr McGreevy is an experienced and successful executive with over 30 years commercial experience in the consumer healthcare and products industry. He has a strong track record of demonstrating commercial success in Omni-channel sales across FMCG and is experienced in franchise, wholesale and manufacturing, as well as having established credentials in internationalising consumer products and businesses.

Mr McGreevy spent his early career with Walgreen Boots Alliance in the UK in R&D, sales, and marketing between 1993 & 1999. This was followed by a period at Dewhirst Group as R&D and Commercial Director. He joined The Body Shop International in 2004 as Global Product Director, then moving on to become Global Operations Director, having additional responsibilities of R&D, acquisitions and divestments. During his 10 years at The Body Shop, he had responsibilities to over 70 markets and oversaw significant growth and expansion of the business.

Since leaving The Body Shop, Mr McGreevy has pursued a successful Non-executive career, as both Chair and Non-executive Director of several international consumer product businesses. He has current board appointments in consumer businesses with a focus on brand, product development, operations, and R&D, with Danish retail chain, Normal A/S, and cosmetics manufacturing company, SnJ International Limited, whilst also also running his own consultancy business, McGreevy Consulting Ltd.

 

Jerry Randall, CEO of Venture Life commented: "We are delighted to have Paul join the Board of Venture Life Group as our new Non-executive Chair. His extensive experience in the international consumer healthcare market will be invaluable to us. In particular, Paul's knowledge of the omni-channel approach to sales and marketing is very pertinent to us as we seek to grow our brands and our business through the many channels available to us in today's market. As an experienced board Director and Chair, Paul brings additional and considerable governance experience to our Board, and we look forward to working with him.

On behalf of the whole Board, I also extend our deepest thanks and gratitude to our outgoing Chair, Dr Lynn Drummond. Lynn has been with us since before our IPO in 2014 and has helped us navigate the difficult path of becoming a growing and sustainably profitable consumer healthcare business on the public markets. We thank Lynn for her time with us and wish her all the very best for the future.

Paul McGreevy commented: "I am very excited to join such an ambitious team, with a great portfolio of brands that provides a solid foundation to accelerate our growth in the self-care sector. VLG is well placed in a growing market to further develop its brands, expand through acquisition, and increase its international footprint." 

 

Further information on Paul McGreevy

Paul Brian McGreevy (aged 54) has held the following directorships in the past 5 years:

Current Directorships:

· McGreevy Consulting Ltd

· S&J International (UK) Limited

· Normal A/S

Previous Directorships held in the past 5 years:

· Age UK Lancashire

· Kennelpak Group Ltd

· Kennelpak Holdings Ltd

There is no further information on Paul McGreevy required to be disclosed under Schedule Two, paragraph (g) of the AIM Rules for Companies.

 

For further information, please contact:

 

Venture Life Group PLC

+44 (0) 1344 578004

Jerry Randall, Chief Executive Officer

Daniel Wells, Chief Financial Officer

 

Cenkos Securities plc (Nomad and Joint Broker)

 

+44 (0) 20 7397 8900

Michael Johnson/Russell Kerr (Sales)

Stephen Keys/Camilla Hume (Corporate Finance)

 

 

Singer Capital Markets (Joint Broker)

 

+44 (0) 20 7496 3000

Jonathan Dighe (Sales)

Shaun Dobson/Alaina Wong (Corporate Finance)

 

 

About Venture Life (www.venture-life.com)

Venture Life is an international consumer self-care company focused on developing, manufacturing and commercialising products for the global self-care market. With operations in the UK, Italy, The Netherlands and Sweden, the Group's product portfolio includes some key products such as the UltraDEX and Dentyl oral care product ranges, the Balance Active range in the area of women's intimate healthcare, the Lift and Glucogel product ranges for hypoglycaemia, products for fungal infections and proctology, and dermo-cosmetics for addressing the signs of ageing. Its products are sold in over 90 countries worldwide.

The products, which are typically recommended by pharmacists or healthcare practitioners, are available primarily through pharmacies and grocery multiples. In the UK and The Netherlands these are supplied direct by the company to retailers, elsewhere they are supplied by the Group's international distribution partners. 

Through its two Development & Manufacturing operations in Italy and Sweden, the Group also provides development and manufacturing services to companies in the medical devices and cosmetic sectors.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOAKZGMKVVNGZZM
Date   Source Headline
25th Nov 20257:00 amRNSTransaction in Own Shares
21st Nov 20257:00 amRNSTransaction in Own Shares
20th Nov 20257:00 amRNSTransaction in Own Shares
19th Nov 20257:00 amRNSTransaction in Own Shares
18th Nov 20257:00 amRNSTransaction in Own Shares
3rd Oct 20254:40 pmRNSDirector/PDMR Shareholding
30th Sep 20257:01 amRNSShare Buyback Programme
30th Sep 20257:00 amRNSInterim Results
29th Sep 202512:19 pmRNSInvestor Presentation via Investor Meet Company
24th Sep 20252:38 pmRNSChange of Accounting Reference Date
8th Sep 20257:00 amRNSDirectorate Change
19th Aug 20252:04 pmRNSHolding(s) in Company
5th Aug 20253:43 pmRNSResult of General Meeting
25th Jul 20257:05 amRNSGrant of Share Options
25th Jul 20257:00 amRNSCompletion of Divestment & Trading Update
7th Jul 20254:21 pmRNSDirector/PDMR Shareholding
3rd Jul 20257:00 amRNSDirector Dealings
2nd Jul 20257:00 amRNSNotice of General Meeting & Investor Presentation
1st Jul 20254:08 pmRNSHolding(s) in Company
30th Jun 20253:15 pmRNSResult of AGM
30th Jun 20253:13 pmRNSFinal Results for year ended 31 December 2024
5th Jun 20252:19 pmRNSNotice of Annual General Meeting
19th May 20257:01 amRNSDirector Dealings
19th May 20257:00 amRNSBoard Update
12th May 20258:49 amRNSReplacement: Cash sale of CDMO operations
12th May 20257:00 amRNSCash sale of CDMO operations
28th Apr 202510:50 amRNSHolding(s) in Company
8th Apr 20254:53 pmRNSHolding(s) in Company
20th Feb 20251:14 pmRNSHolding(s) in Company
18th Feb 202510:02 amRNSHolding(s) in Company
4th Feb 20257:01 amRNSBoard Changes
4th Feb 20257:00 amRNSTrading Statement
21st Jan 20258:15 amRNSExercise of Share Options & Total Voting Rights
20th Jan 202511:49 amRNSHolding(s) in Company
19th Dec 202411:48 amRNSHolding(s) in Company
4th Nov 20243:44 pmRNSHolding(s) in Company
30th Oct 202412:01 pmRNSDirector/PDMR Shareholding
30th Oct 202410:58 amRNSDirector/PDMR Shareholding
30th Oct 20247:00 amRNSAcquisition of Health & Her Limited
1st Oct 202412:47 pmRNSHolding(s) in Company
30th Sep 20247:00 amRNSInterim Results
26th Sep 20247:00 amRNSInvestor Presentation via Investor Meet Company
2nd Sep 202410:41 amRNSDirector/PDMR Shareholding
2nd Sep 202410:40 amRNSReplacement - Exercise of Options & TVR
23rd Aug 20247:00 amRNSExercise of Options, Director Dealings & TVR
9th Aug 20241:17 pmRNSHolding(s) in Company
6th Aug 20247:00 amRNSTrading Update
25th Jul 20243:54 pmRNSHolding(s) in Company
11th Jul 202410:08 amRNSHolding(s) in Company
19th Jun 20242:46 pmRNSPosting of Annual Report

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.